SlideShare a Scribd company logo
1 of 32
Antiretroviral Chemoprophylaxis: What have we learned so far? Kenneth H. Mayer, MD March 26 th , 2011 Search for A Cure
HIV Prevention: Current Targets Condom and HIV testing promotion Individual interventions Couples interventions Community-based interventions Structural interventions Barrier protection Blood screening IDU harm reduction Antiretroviral therapy (PMTCT, treat infected partners) STI treatment Barrier protection Infection control Circumcision PEP, PrEP Topical microbicides Vaccines STI treatment Alter Behavior Decrease Host Susceptibility Decrease Source of Infection
Why Antiretroviral Agents for HIV Prevention? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Connor EM, et al.  N Engl J Med.  1994;331:1173-1180. Cardo DM, et al.  N Engl J Med.  1997;337:1485-1490. Grant RM, et al.  Clin Infect Dis.  2010;50(suppl 3):S96-S101. Venkatesh KK, et al.  Future Virol.  2010;5:405-415.
Per-Act Risk for HIV Acquisition  01/05 Exposure Route Risk per 10,000 exposures  Blood transfusion 9,000 Needle-sharing injection drug use 67 Receptive anal intercourse 50 Percutaneous needle stick 30 Receptive penile-vaginal intercourse 10 Insertive anal intercourse 6.5 Insertive penile-vaginal intercourse 10 Receptive oral intercourse 1 Insertive oral intercourse 0.5
Not all ART may be equal for Prevention: Ratio of Genital:Blood Plasma Levels Nicol MR, et al.  Clin Pharmacol Ther.  2010;88:598-609. Women Men Genital Tract:Blood Plasma AUC Ratio of 1.0: genital tract AUC=blood plasma AUC. Genital tract exposure within 2 and 1 hour of dosing for women and men, respectively. NRTI NNRTI PI Entry Inhibitor INSTI 6.0 5.0 4.0 3.0 2.0 1.0 0.5 0 ddI ABC d4T APV RTV ATV LPV SQV Genital Tract:Blood Plasma AUC NRTI NNRTI PI Entry Inhibitor INSTI 6.0 5.0 4.0 3.0 2.0 1.0 0.5 0 d4T APV, ATV,LPV DRV,SQV, RTV TDF ZDV FTC 3TC ETV NVP EFV DRV IDV MRV RAL TDF ZDV 3TC FTC NVP EFV IDV MRV RAL ABC
PEP: Guidelines
PEP vs. PrEP ,[object Object],[object Object],[object Object],[object Object],[object Object]
PEP: Fenway Experience ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Mayer et al, JAIDS, 47:494-99, 2008
PEP: Guidelines ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Bassett IV, et al.  CID.  2004;39:395-401. Mayer KH, et al. AJPH. 2010;100:1867-1876
 
 
 
 
 
 
 
 
Drug Resistance Grant et al, CROI 2010 Genotypic Resistance HIV Status at Enrollment Infected Uninfected Placebo N=8 FTC/TDF N=2 Placebo N=83 FTC/TDF N=48 65R 0 (0%) 0 (0%) 0 (0%) 0 (0%) 70E 0 (0%) 0 (0%) 0 (0%) 0 (0%) 184I 0 (0%) 1 (50%) 0 (0%) 0 (0%) 184V 1 (13%) 1 (50%) 0 (0%) 0 (0%) TDF Resistance 0 (0%) 0 (0%) 0 (0%) 0 (0%) FTC Resistance 1 (13%) 2 (100%) 0 (0%) 0 (0%)
Topical TDF or FTC/TDF Gel: Complete Protection From SHIV Exposures Protection From SHIV Uninfected (%) 1% TDF  (n=6) Challenges 0  2  4  6  8  10  12  14  16  18  20 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Parikh UM, et al.  J Virol.  2009;83:10358-10365. 5% FTC/1% TDF  (n=6) Placebo Gel (n=9) No Gel (n=2) SHIV: simian (SIV)-human (HIV) hybrid.
CAPRISA 004 Results: HIV Incidence Abdool Karim Q, et al.  Science.  2010;329:1168-1174. HIV Incidence Rate (%) 12 30 10.5% 5.2% 9.1% 5.6% Follow-Up (months) 50% ( P =0.007) 39% ( P =0.017) Overall Placebo Tenofovir DF gel HIV Incidence Rate (%) >80% 9.3% 4.2% 10.0% 8.6% 54% ( P =0.025) 38% ( P =0.34) By Adherence Placebo Tenofovir DF gel 6.3% 6.2% 28% ( P =0.30) 50%-80% <50% Adherence Level (months)
Investigation: Ongoing PrEP efficacy studies  ,[object Object],Location Sponsor/ Funder Population N PrEP Agent Status Thailand Bangkok Tenofovir Study CDC IDU 2400  TDF Fully  enrolled Results 2012 Kenya, Uganda Partners PrEP Study UW / BMGF HIV discordant couples 4758 TDF, FTC/TDF Fully enrolled Results 2012 Kenya, South Africa , Tanzania, Zimbabwe FEM-PrEP FHI / USAID & BMGF Women 3900 FTC/TDF 49% enrolled  Results 2013 South Africa, Uganda, Zimbabwe  VOICE / MTN 003 MTN / NIH Women 5000 TDF, FTC/TDF, Vaginal tenofovir gel ( daily ) 65% enrolled  Results 2013
Peri-Exposure Prophylaxis in Macaques With Oral FTC/TDF Protection From SHIV Uninfected (%) Rectal Exposures (number) 0  2  4  6  8  10  12  14 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Garcia-Lerma JG, et al.  Sci Transl Med.  2010;2:14ra4. FTC/TDF Dosing HR -22h/+2h -3d/+2h -7d/+2h -2h/+22h 16.7 15.4 9.4 4.1 Untreated Controls P Value .006 .008 .003 .02
What about intermittant PrEP?   ,[object Object],[object Object],[object Object]
Human studies of intermittent PrEP ,[object Object],[object Object],[object Object],[object Object],Dosing strategy HIV discordant couples, Uganda (N=72) High risk women & MSM, Kenya (N=72) Daily dosing, adjusted rate 96-97% 82-92% Fixed twice weekly dosing 91% 55% Post-coital dosing 45% 26%
What about rectal gel? ,[object Object],[object Object],[object Object],[object Object],[object Object]
New Antiretroviral Topical Microbicides
PrEP Delivery Platforms:  Long-acting topical & systemic delivery Gel with applicator Vaginal ring (sustained delivery) ,[object Object],[object Object],[object Object],[object Object],Vaginal film Injectable (long-acting) Pill
PREP: Guidelines
Combination Antiretroviral Prevention Modified from www.hptn.org. Decrease in HIV Transmission Maintain Viral Suppression Treat Enroll in Care Address  concomitant concerns,  e.g. depression, substance use, relationship dynamics HIV Negative Test Interventions to Increase Testing  Positive Prevention Linkage To Care Adherence to ART ART Initiation Risk Assessment PrEP, Adherence Counseling HIV Positive
Optimizing ART for Prevention ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Many thanks ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

More Related Content

What's hot

Journal club presentation: by RxVichuZ!! ;)
Journal club presentation: by RxVichuZ!! ;)Journal club presentation: by RxVichuZ!! ;)
Journal club presentation: by RxVichuZ!! ;)RxVichuZ
 
Incorporating New ART Options Into First-line and Switch Strategies for HIV C...
Incorporating New ART Options Into First-line and Switch Strategies for HIV C...Incorporating New ART Options Into First-line and Switch Strategies for HIV C...
Incorporating New ART Options Into First-line and Switch Strategies for HIV C...hivlifeinfo
 
Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...
Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...
Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...Hivlife Info
 
Final Journal Club Presentation
Final Journal Club PresentationFinal Journal Club Presentation
Final Journal Club PresentationAnna Schemel
 
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...hivlifeinfo
 
D3 Retroviral Review Duffus
D3 Retroviral Review DuffusD3 Retroviral Review Duffus
D3 Retroviral Review DuffusDSHS
 
Antiretroviral Therapy Update 2014
Antiretroviral Therapy Update 2014Antiretroviral Therapy Update 2014
Antiretroviral Therapy Update 2014Hivlife Info
 
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.CBRC
 
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...Hivlife Info
 
Michael Festing - MedicReS World Congress 2011
Michael Festing - MedicReS World Congress 2011Michael Festing - MedicReS World Congress 2011
Michael Festing - MedicReS World Congress 2011MedicReS
 
HIV Alert:Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents ...
HIV Alert:Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents ...HIV Alert:Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents ...
HIV Alert:Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents ...hivlifeinfo
 
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014Hivlife Info
 
New perspectives in the treatment of multidrug-resistant tuberculosis - Profe...
New perspectives in the treatment of multidrug-resistant tuberculosis - Profe...New perspectives in the treatment of multidrug-resistant tuberculosis - Profe...
New perspectives in the treatment of multidrug-resistant tuberculosis - Profe...WAidid
 
What’s New in Coformulated Antiretroviral Regimens.2014
What’s New in Coformulated Antiretroviral Regimens.2014What’s New in Coformulated Antiretroviral Regimens.2014
What’s New in Coformulated Antiretroviral Regimens.2014Hivlife Info
 
Lancet_Manns et al 2014
Lancet_Manns et al 2014Lancet_Manns et al 2014
Lancet_Manns et al 2014Eric A. Hughes
 
Sepsis and antibiotic guidance in neurology wards
Sepsis and antibiotic guidance in neurology wardsSepsis and antibiotic guidance in neurology wards
Sepsis and antibiotic guidance in neurology wardsDivya Shilpa
 

What's hot (20)

Journal club presentation: by RxVichuZ!! ;)
Journal club presentation: by RxVichuZ!! ;)Journal club presentation: by RxVichuZ!! ;)
Journal club presentation: by RxVichuZ!! ;)
 
Incorporating New ART Options Into First-line and Switch Strategies for HIV C...
Incorporating New ART Options Into First-line and Switch Strategies for HIV C...Incorporating New ART Options Into First-line and Switch Strategies for HIV C...
Incorporating New ART Options Into First-line and Switch Strategies for HIV C...
 
Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...
Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...
Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...
 
Final Journal Club Presentation
Final Journal Club PresentationFinal Journal Club Presentation
Final Journal Club Presentation
 
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...
Современное лечение ВИЧ: модификация АРТ у пациентов с вирусологической супре...
 
Update on HIV Prevention Issues Presented at 2016 CROI
Update on HIV Prevention Issues Presented at 2016 CROIUpdate on HIV Prevention Issues Presented at 2016 CROI
Update on HIV Prevention Issues Presented at 2016 CROI
 
Dept. of Food Safety and Zoonoses (FOS)
Dept. of Food Safety and Zoonoses (FOS)Dept. of Food Safety and Zoonoses (FOS)
Dept. of Food Safety and Zoonoses (FOS)
 
D3 Retroviral Review Duffus
D3 Retroviral Review DuffusD3 Retroviral Review Duffus
D3 Retroviral Review Duffus
 
Prostate
ProstateProstate
Prostate
 
Antiretroviral Therapy Update 2014
Antiretroviral Therapy Update 2014Antiretroviral Therapy Update 2014
Antiretroviral Therapy Update 2014
 
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.
 
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...
Highlights of AIDS 2014 .CCO Official Conference Coverage of the 20th Interna...
 
Michael Festing - MedicReS World Congress 2011
Michael Festing - MedicReS World Congress 2011Michael Festing - MedicReS World Congress 2011
Michael Festing - MedicReS World Congress 2011
 
HIV Alert:Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents ...
HIV Alert:Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents ...HIV Alert:Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents ...
HIV Alert:Новые стратегии и агенты в лечении ВИЧ/Novel Strategies and Agents ...
 
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014
The Role of New HCV Agents in Managing HIV/HCV Coinfection.2014
 
ACTG 5273
ACTG 5273ACTG 5273
ACTG 5273
 
New perspectives in the treatment of multidrug-resistant tuberculosis - Profe...
New perspectives in the treatment of multidrug-resistant tuberculosis - Profe...New perspectives in the treatment of multidrug-resistant tuberculosis - Profe...
New perspectives in the treatment of multidrug-resistant tuberculosis - Profe...
 
What’s New in Coformulated Antiretroviral Regimens.2014
What’s New in Coformulated Antiretroviral Regimens.2014What’s New in Coformulated Antiretroviral Regimens.2014
What’s New in Coformulated Antiretroviral Regimens.2014
 
Lancet_Manns et al 2014
Lancet_Manns et al 2014Lancet_Manns et al 2014
Lancet_Manns et al 2014
 
Sepsis and antibiotic guidance in neurology wards
Sepsis and antibiotic guidance in neurology wardsSepsis and antibiotic guidance in neurology wards
Sepsis and antibiotic guidance in neurology wards
 

Viewers also liked

Microbicides for hiv prevention
Microbicides for hiv preventionMicrobicides for hiv prevention
Microbicides for hiv preventionSetegn Eshetie
 
Human resource management ppt 2
Human resource management  ppt 2Human resource management  ppt 2
Human resource management ppt 2Sameer Ahmed
 
Prevention Of HIV/AIDS
Prevention Of HIV/AIDSPrevention Of HIV/AIDS
Prevention Of HIV/AIDSSoumar Dutta
 

Viewers also liked (6)

Microbicides for hiv prevention
Microbicides for hiv preventionMicrobicides for hiv prevention
Microbicides for hiv prevention
 
Introduction To HRM
Introduction To HRMIntroduction To HRM
Introduction To HRM
 
Human resource management ppt 2
Human resource management  ppt 2Human resource management  ppt 2
Human resource management ppt 2
 
Hiv prevention powerpoint
Hiv prevention powerpointHiv prevention powerpoint
Hiv prevention powerpoint
 
Prevention Of HIV/AIDS
Prevention Of HIV/AIDSPrevention Of HIV/AIDS
Prevention Of HIV/AIDS
 
hrm functions
hrm functionshrm functions
hrm functions
 

Similar to Prophylaxis and HIV Prevention by Dr. Ken Mayer

Contemporary Management of HIV. New Data From AIDS 2018
Contemporary Management of HIV. New Data From AIDS 2018Contemporary Management of HIV. New Data From AIDS 2018
Contemporary Management of HIV. New Data From AIDS 2018hivlifeinfo
 
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...hivlifeinfo
 
Pep and prep cahill
Pep and prep cahillPep and prep cahill
Pep and prep cahillhealthhiv
 
The 18th International AIDS Conference (AIDS 2010)
The 18th International AIDS Conference (AIDS 2010)The 18th International AIDS Conference (AIDS 2010)
The 18th International AIDS Conference (AIDS 2010)Abhishek Shah
 
Clinical Impact of New HIV Data From CROI 2019
Clinical Impact of New HIV Data From CROI 2019Clinical Impact of New HIV Data From CROI 2019
Clinical Impact of New HIV Data From CROI 2019hivlifeinfo
 
Cовременное лечение ВИЧ : новые данные с конференции CROI 2017/ Contemporary...
Cовременное лечение ВИЧ : новые данные с  конференции CROI 2017/ Contemporary...Cовременное лечение ВИЧ : новые данные с  конференции CROI 2017/ Contemporary...
Cовременное лечение ВИЧ : новые данные с конференции CROI 2017/ Contemporary...hivlifeinfo
 
Drug Therapy For Prevention?
Drug Therapy For Prevention?Drug Therapy For Prevention?
Drug Therapy For Prevention?CHAMP Network
 
Aidsrounds121412morris 121214115641-phpapp01
Aidsrounds121412morris 121214115641-phpapp01Aidsrounds121412morris 121214115641-phpapp01
Aidsrounds121412morris 121214115641-phpapp01Lucas Brown
 
Innovative Paradigms for ART.2019
Innovative Paradigms for ART.2019Innovative Paradigms for ART.2019
Innovative Paradigms for ART.2019hivlifeinfo
 
Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...
Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...
Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...hivlifeinfo
 
Management of HIV - Post-Exposure Prophylaxis Management of HIV - Post-Expo...
Management of HIV - Post-Exposure Prophylaxis 	 Management of HIV - Post-Expo...Management of HIV - Post-Exposure Prophylaxis 	 Management of HIV - Post-Expo...
Management of HIV - Post-Exposure Prophylaxis Management of HIV - Post-Expo...MedicineAndHealthUSA
 
Современное лечение ВИЧ : АРТ как профилактика.Contemporary Management of HIV...
Современное лечение ВИЧ : АРТ как профилактика.Contemporary Management of HIV...Современное лечение ВИЧ : АРТ как профилактика.Contemporary Management of HIV...
Современное лечение ВИЧ : АРТ как профилактика.Contemporary Management of HIV...hivlifeinfo
 
Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...
Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...
Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...hivlifeinfo
 
Tratamiento Antirretroviral coformulado con un IP
Tratamiento Antirretroviral coformulado con un IPTratamiento Antirretroviral coformulado con un IP
Tratamiento Antirretroviral coformulado con un IPPablo Francisco Parenti
 
HPG PrEP Presentation by Dr. Kathleen Brady (AACO)
HPG PrEP Presentation by Dr. Kathleen Brady (AACO)HPG PrEP Presentation by Dr. Kathleen Brady (AACO)
HPG PrEP Presentation by Dr. Kathleen Brady (AACO)Office of HIV Planning
 
It’s Time for PrEP (Kathleen Brady, Philadelphia Department of Public Health)
It’s Time for PrEP (Kathleen Brady, Philadelphia Department of Public Health)It’s Time for PrEP (Kathleen Brady, Philadelphia Department of Public Health)
It’s Time for PrEP (Kathleen Brady, Philadelphia Department of Public Health)Office of HIV Planning
 
Beta Lactam: To Extend or not to Extend: That is the Question!
Beta Lactam: To Extend or not to Extend: That is the Question!Beta Lactam: To Extend or not to Extend: That is the Question!
Beta Lactam: To Extend or not to Extend: That is the Question!munaoqal
 
Targeted Therapy for Melanoma - Dr. Michael Davies
Targeted Therapy for Melanoma - Dr. Michael DaviesTargeted Therapy for Melanoma - Dr. Michael Davies
Targeted Therapy for Melanoma - Dr. Michael DaviesMelanoma Research Foundation
 

Similar to Prophylaxis and HIV Prevention by Dr. Ken Mayer (20)

Contemporary Management of HIV. New Data From AIDS 2018
Contemporary Management of HIV. New Data From AIDS 2018Contemporary Management of HIV. New Data From AIDS 2018
Contemporary Management of HIV. New Data From AIDS 2018
 
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...
 
Pep and prep cahill
Pep and prep cahillPep and prep cahill
Pep and prep cahill
 
The 18th International AIDS Conference (AIDS 2010)
The 18th International AIDS Conference (AIDS 2010)The 18th International AIDS Conference (AIDS 2010)
The 18th International AIDS Conference (AIDS 2010)
 
Clinical Impact of New HIV Data From CROI 2019
Clinical Impact of New HIV Data From CROI 2019Clinical Impact of New HIV Data From CROI 2019
Clinical Impact of New HIV Data From CROI 2019
 
Cco ias 2013_new_data
Cco ias 2013_new_dataCco ias 2013_new_data
Cco ias 2013_new_data
 
Cовременное лечение ВИЧ : новые данные с конференции CROI 2017/ Contemporary...
Cовременное лечение ВИЧ : новые данные с  конференции CROI 2017/ Contemporary...Cовременное лечение ВИЧ : новые данные с  конференции CROI 2017/ Contemporary...
Cовременное лечение ВИЧ : новые данные с конференции CROI 2017/ Contemporary...
 
Drug Therapy For Prevention?
Drug Therapy For Prevention?Drug Therapy For Prevention?
Drug Therapy For Prevention?
 
Aidsrounds121412morris 121214115641-phpapp01
Aidsrounds121412morris 121214115641-phpapp01Aidsrounds121412morris 121214115641-phpapp01
Aidsrounds121412morris 121214115641-phpapp01
 
Innovative Paradigms for ART.2019
Innovative Paradigms for ART.2019Innovative Paradigms for ART.2019
Innovative Paradigms for ART.2019
 
Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...
Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...
Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...
 
Management of HIV - Post-Exposure Prophylaxis Management of HIV - Post-Expo...
Management of HIV - Post-Exposure Prophylaxis 	 Management of HIV - Post-Expo...Management of HIV - Post-Exposure Prophylaxis 	 Management of HIV - Post-Expo...
Management of HIV - Post-Exposure Prophylaxis Management of HIV - Post-Expo...
 
Biomedical HIV prevention
Biomedical HIV preventionBiomedical HIV prevention
Biomedical HIV prevention
 
Современное лечение ВИЧ : АРТ как профилактика.Contemporary Management of HIV...
Современное лечение ВИЧ : АРТ как профилактика.Contemporary Management of HIV...Современное лечение ВИЧ : АРТ как профилактика.Contemporary Management of HIV...
Современное лечение ВИЧ : АРТ как профилактика.Contemporary Management of HIV...
 
Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...
Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...
Современное лечение ВИЧ: лечение ВИЧ у женщин.2017/Contemporary Management of...
 
Tratamiento Antirretroviral coformulado con un IP
Tratamiento Antirretroviral coformulado con un IPTratamiento Antirretroviral coformulado con un IP
Tratamiento Antirretroviral coformulado con un IP
 
HPG PrEP Presentation by Dr. Kathleen Brady (AACO)
HPG PrEP Presentation by Dr. Kathleen Brady (AACO)HPG PrEP Presentation by Dr. Kathleen Brady (AACO)
HPG PrEP Presentation by Dr. Kathleen Brady (AACO)
 
It’s Time for PrEP (Kathleen Brady, Philadelphia Department of Public Health)
It’s Time for PrEP (Kathleen Brady, Philadelphia Department of Public Health)It’s Time for PrEP (Kathleen Brady, Philadelphia Department of Public Health)
It’s Time for PrEP (Kathleen Brady, Philadelphia Department of Public Health)
 
Beta Lactam: To Extend or not to Extend: That is the Question!
Beta Lactam: To Extend or not to Extend: That is the Question!Beta Lactam: To Extend or not to Extend: That is the Question!
Beta Lactam: To Extend or not to Extend: That is the Question!
 
Targeted Therapy for Melanoma - Dr. Michael Davies
Targeted Therapy for Melanoma - Dr. Michael DaviesTargeted Therapy for Melanoma - Dr. Michael Davies
Targeted Therapy for Melanoma - Dr. Michael Davies
 

Recently uploaded

Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...
Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...
Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...amritaverma53
 
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana GuptaLifecare Centre
 
Call Girls in Lucknow Just Call 👉👉8630512678 Top Class Call Girl Service Avai...
Call Girls in Lucknow Just Call 👉👉8630512678 Top Class Call Girl Service Avai...Call Girls in Lucknow Just Call 👉👉8630512678 Top Class Call Girl Service Avai...
Call Girls in Lucknow Just Call 👉👉8630512678 Top Class Call Girl Service Avai...soniyagrag336
 
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...Sheetaleventcompany
 
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...Cara Menggugurkan Kandungan 087776558899
 
Gorgeous Call Girls Dehradun {8854095900} ❤️VVIP ROCKY Call Girls in Dehradun...
Gorgeous Call Girls Dehradun {8854095900} ❤️VVIP ROCKY Call Girls in Dehradun...Gorgeous Call Girls Dehradun {8854095900} ❤️VVIP ROCKY Call Girls in Dehradun...
Gorgeous Call Girls Dehradun {8854095900} ❤️VVIP ROCKY Call Girls in Dehradun...Sheetaleventcompany
 
(RIYA)🎄Airhostess Call Girl Jaipur Call Now 8445551418 Premium Collection Of ...
(RIYA)🎄Airhostess Call Girl Jaipur Call Now 8445551418 Premium Collection Of ...(RIYA)🎄Airhostess Call Girl Jaipur Call Now 8445551418 Premium Collection Of ...
(RIYA)🎄Airhostess Call Girl Jaipur Call Now 8445551418 Premium Collection Of ...TanyaAhuja34
 
Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...
Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...
Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...Sheetaleventcompany
 
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...gragneelam30
 
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...Sheetaleventcompany
 
Circulatory Shock, types and stages, compensatory mechanisms
Circulatory Shock, types and stages, compensatory mechanismsCirculatory Shock, types and stages, compensatory mechanisms
Circulatory Shock, types and stages, compensatory mechanismsMedicoseAcademics
 
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...Oleg Kshivets
 
💚Chandigarh Call Girls Service 💯Piya 📲🔝8868886958🔝Call Girls In Chandigarh No...
💚Chandigarh Call Girls Service 💯Piya 📲🔝8868886958🔝Call Girls In Chandigarh No...💚Chandigarh Call Girls Service 💯Piya 📲🔝8868886958🔝Call Girls In Chandigarh No...
💚Chandigarh Call Girls Service 💯Piya 📲🔝8868886958🔝Call Girls In Chandigarh No...Sheetaleventcompany
 
Pune Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Pune No💰Adva...
Pune Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Pune No💰Adva...Pune Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Pune No💰Adva...
Pune Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Pune No💰Adva...Sheetaleventcompany
 
Call Girls in Lucknow Just Call 👉👉 8875999948 Top Class Call Girl Service Ava...
Call Girls in Lucknow Just Call 👉👉 8875999948 Top Class Call Girl Service Ava...Call Girls in Lucknow Just Call 👉👉 8875999948 Top Class Call Girl Service Ava...
Call Girls in Lucknow Just Call 👉👉 8875999948 Top Class Call Girl Service Ava...Janvi Singh
 
Kolkata Call Girls Shobhabazar 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Gir...
Kolkata Call Girls Shobhabazar  💯Call Us 🔝 8005736733 🔝 💃  Top Class Call Gir...Kolkata Call Girls Shobhabazar  💯Call Us 🔝 8005736733 🔝 💃  Top Class Call Gir...
Kolkata Call Girls Shobhabazar 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Gir...Namrata Singh
 
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...call girls hydrabad
 
Kolkata Call Girls Service ❤️🍑 9xx000xx09 👄🫦 Independent Escort Service Kolka...
Kolkata Call Girls Service ❤️🍑 9xx000xx09 👄🫦 Independent Escort Service Kolka...Kolkata Call Girls Service ❤️🍑 9xx000xx09 👄🫦 Independent Escort Service Kolka...
Kolkata Call Girls Service ❤️🍑 9xx000xx09 👄🫦 Independent Escort Service Kolka...Sheetaleventcompany
 
Kolkata Call Girls Naktala 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
Kolkata Call Girls Naktala  💯Call Us 🔝 8005736733 🔝 💃  Top Class Call Girl Se...Kolkata Call Girls Naktala  💯Call Us 🔝 8005736733 🔝 💃  Top Class Call Girl Se...
Kolkata Call Girls Naktala 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...Namrata Singh
 
👉 Chennai Sexy Aunty’s WhatsApp Number 👉📞 7427069034 👉📞 Just📲 Call Ruhi Colle...
👉 Chennai Sexy Aunty’s WhatsApp Number 👉📞 7427069034 👉📞 Just📲 Call Ruhi Colle...👉 Chennai Sexy Aunty’s WhatsApp Number 👉📞 7427069034 👉📞 Just📲 Call Ruhi Colle...
👉 Chennai Sexy Aunty’s WhatsApp Number 👉📞 7427069034 👉📞 Just📲 Call Ruhi Colle...rajnisinghkjn
 

Recently uploaded (20)

Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...
Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...
Call Girl in Chennai | Whatsapp No 📞 7427069034 📞 VIP Escorts Service Availab...
 
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
7 steps How to prevent Thalassemia : Dr Sharda Jain & Vandana Gupta
 
Call Girls in Lucknow Just Call 👉👉8630512678 Top Class Call Girl Service Avai...
Call Girls in Lucknow Just Call 👉👉8630512678 Top Class Call Girl Service Avai...Call Girls in Lucknow Just Call 👉👉8630512678 Top Class Call Girl Service Avai...
Call Girls in Lucknow Just Call 👉👉8630512678 Top Class Call Girl Service Avai...
 
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...
Goa Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Goa No💰Advanc...
 
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
Cara Menggugurkan Kandungan Dengan Cepat Selesai Dalam 24 Jam Secara Alami Bu...
 
Gorgeous Call Girls Dehradun {8854095900} ❤️VVIP ROCKY Call Girls in Dehradun...
Gorgeous Call Girls Dehradun {8854095900} ❤️VVIP ROCKY Call Girls in Dehradun...Gorgeous Call Girls Dehradun {8854095900} ❤️VVIP ROCKY Call Girls in Dehradun...
Gorgeous Call Girls Dehradun {8854095900} ❤️VVIP ROCKY Call Girls in Dehradun...
 
(RIYA)🎄Airhostess Call Girl Jaipur Call Now 8445551418 Premium Collection Of ...
(RIYA)🎄Airhostess Call Girl Jaipur Call Now 8445551418 Premium Collection Of ...(RIYA)🎄Airhostess Call Girl Jaipur Call Now 8445551418 Premium Collection Of ...
(RIYA)🎄Airhostess Call Girl Jaipur Call Now 8445551418 Premium Collection Of ...
 
Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...
Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...
Chandigarh Call Girls Service ❤️🍑 9809698092 👄🫦Independent Escort Service Cha...
 
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...
💰Call Girl In Bangalore☎️63788-78445💰 Call Girl service in Bangalore☎️Bangalo...
 
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
💚Call Girls In Amritsar 💯Anvi 📲🔝8725944379🔝Amritsar Call Girl No💰Advance Cash...
 
Circulatory Shock, types and stages, compensatory mechanisms
Circulatory Shock, types and stages, compensatory mechanismsCirculatory Shock, types and stages, compensatory mechanisms
Circulatory Shock, types and stages, compensatory mechanisms
 
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
Gastric Cancer: Сlinical Implementation of Artificial Intelligence, Synergeti...
 
💚Chandigarh Call Girls Service 💯Piya 📲🔝8868886958🔝Call Girls In Chandigarh No...
💚Chandigarh Call Girls Service 💯Piya 📲🔝8868886958🔝Call Girls In Chandigarh No...💚Chandigarh Call Girls Service 💯Piya 📲🔝8868886958🔝Call Girls In Chandigarh No...
💚Chandigarh Call Girls Service 💯Piya 📲🔝8868886958🔝Call Girls In Chandigarh No...
 
Pune Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Pune No💰Adva...
Pune Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Pune No💰Adva...Pune Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Pune No💰Adva...
Pune Call Girl Service 📞9xx000xx09📞Just Call Divya📲 Call Girl In Pune No💰Adva...
 
Call Girls in Lucknow Just Call 👉👉 8875999948 Top Class Call Girl Service Ava...
Call Girls in Lucknow Just Call 👉👉 8875999948 Top Class Call Girl Service Ava...Call Girls in Lucknow Just Call 👉👉 8875999948 Top Class Call Girl Service Ava...
Call Girls in Lucknow Just Call 👉👉 8875999948 Top Class Call Girl Service Ava...
 
Kolkata Call Girls Shobhabazar 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Gir...
Kolkata Call Girls Shobhabazar  💯Call Us 🔝 8005736733 🔝 💃  Top Class Call Gir...Kolkata Call Girls Shobhabazar  💯Call Us 🔝 8005736733 🔝 💃  Top Class Call Gir...
Kolkata Call Girls Shobhabazar 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Gir...
 
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...
Call girls Service Phullen / 9332606886 Genuine Call girls with real Photos a...
 
Kolkata Call Girls Service ❤️🍑 9xx000xx09 👄🫦 Independent Escort Service Kolka...
Kolkata Call Girls Service ❤️🍑 9xx000xx09 👄🫦 Independent Escort Service Kolka...Kolkata Call Girls Service ❤️🍑 9xx000xx09 👄🫦 Independent Escort Service Kolka...
Kolkata Call Girls Service ❤️🍑 9xx000xx09 👄🫦 Independent Escort Service Kolka...
 
Kolkata Call Girls Naktala 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
Kolkata Call Girls Naktala  💯Call Us 🔝 8005736733 🔝 💃  Top Class Call Girl Se...Kolkata Call Girls Naktala  💯Call Us 🔝 8005736733 🔝 💃  Top Class Call Girl Se...
Kolkata Call Girls Naktala 💯Call Us 🔝 8005736733 🔝 💃 Top Class Call Girl Se...
 
👉 Chennai Sexy Aunty’s WhatsApp Number 👉📞 7427069034 👉📞 Just📲 Call Ruhi Colle...
👉 Chennai Sexy Aunty’s WhatsApp Number 👉📞 7427069034 👉📞 Just📲 Call Ruhi Colle...👉 Chennai Sexy Aunty’s WhatsApp Number 👉📞 7427069034 👉📞 Just📲 Call Ruhi Colle...
👉 Chennai Sexy Aunty’s WhatsApp Number 👉📞 7427069034 👉📞 Just📲 Call Ruhi Colle...
 

Prophylaxis and HIV Prevention by Dr. Ken Mayer

  • 1. Antiretroviral Chemoprophylaxis: What have we learned so far? Kenneth H. Mayer, MD March 26 th , 2011 Search for A Cure
  • 2. HIV Prevention: Current Targets Condom and HIV testing promotion Individual interventions Couples interventions Community-based interventions Structural interventions Barrier protection Blood screening IDU harm reduction Antiretroviral therapy (PMTCT, treat infected partners) STI treatment Barrier protection Infection control Circumcision PEP, PrEP Topical microbicides Vaccines STI treatment Alter Behavior Decrease Host Susceptibility Decrease Source of Infection
  • 3.
  • 4. Per-Act Risk for HIV Acquisition 01/05 Exposure Route Risk per 10,000 exposures Blood transfusion 9,000 Needle-sharing injection drug use 67 Receptive anal intercourse 50 Percutaneous needle stick 30 Receptive penile-vaginal intercourse 10 Insertive anal intercourse 6.5 Insertive penile-vaginal intercourse 10 Receptive oral intercourse 1 Insertive oral intercourse 0.5
  • 5. Not all ART may be equal for Prevention: Ratio of Genital:Blood Plasma Levels Nicol MR, et al. Clin Pharmacol Ther. 2010;88:598-609. Women Men Genital Tract:Blood Plasma AUC Ratio of 1.0: genital tract AUC=blood plasma AUC. Genital tract exposure within 2 and 1 hour of dosing for women and men, respectively. NRTI NNRTI PI Entry Inhibitor INSTI 6.0 5.0 4.0 3.0 2.0 1.0 0.5 0 ddI ABC d4T APV RTV ATV LPV SQV Genital Tract:Blood Plasma AUC NRTI NNRTI PI Entry Inhibitor INSTI 6.0 5.0 4.0 3.0 2.0 1.0 0.5 0 d4T APV, ATV,LPV DRV,SQV, RTV TDF ZDV FTC 3TC ETV NVP EFV DRV IDV MRV RAL TDF ZDV 3TC FTC NVP EFV IDV MRV RAL ABC
  • 7.
  • 8.
  • 9.
  • 10.  
  • 11.  
  • 12.  
  • 13.  
  • 14.  
  • 15.  
  • 16.  
  • 17.  
  • 18.
  • 19. Drug Resistance Grant et al, CROI 2010 Genotypic Resistance HIV Status at Enrollment Infected Uninfected Placebo N=8 FTC/TDF N=2 Placebo N=83 FTC/TDF N=48 65R 0 (0%) 0 (0%) 0 (0%) 0 (0%) 70E 0 (0%) 0 (0%) 0 (0%) 0 (0%) 184I 0 (0%) 1 (50%) 0 (0%) 0 (0%) 184V 1 (13%) 1 (50%) 0 (0%) 0 (0%) TDF Resistance 0 (0%) 0 (0%) 0 (0%) 0 (0%) FTC Resistance 1 (13%) 2 (100%) 0 (0%) 0 (0%)
  • 20.
  • 21. CAPRISA 004 Results: HIV Incidence Abdool Karim Q, et al. Science. 2010;329:1168-1174. HIV Incidence Rate (%) 12 30 10.5% 5.2% 9.1% 5.6% Follow-Up (months) 50% ( P =0.007) 39% ( P =0.017) Overall Placebo Tenofovir DF gel HIV Incidence Rate (%) >80% 9.3% 4.2% 10.0% 8.6% 54% ( P =0.025) 38% ( P =0.34) By Adherence Placebo Tenofovir DF gel 6.3% 6.2% 28% ( P =0.30) 50%-80% <50% Adherence Level (months)
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 28.
  • 30. Combination Antiretroviral Prevention Modified from www.hptn.org. Decrease in HIV Transmission Maintain Viral Suppression Treat Enroll in Care Address concomitant concerns, e.g. depression, substance use, relationship dynamics HIV Negative Test Interventions to Increase Testing Positive Prevention Linkage To Care Adherence to ART ART Initiation Risk Assessment PrEP, Adherence Counseling HIV Positive
  • 31.
  • 32.

Editor's Notes

  1. Slide: HIV Prevention: Current Targets HIV continues to spread rapidly in developing countries and remain at unacceptable levels in developed countries. These trends are unlikely to change because: 1 Current HIV-prevention strategies are only partially effective and underused. Preventative vaccine remains years away. Current HIV treatment strategies can not eradicate HIV infection.   Increasing attention has therefore focused on whether available antiretroviral drugs could be used to slow the epidemic. However, the initiation of HAART for prevention can manifest differently in diverse social settings, raising concerns over increased sexual risk taking behavior, viral resistance, toxicities, costs, and risk compensation, to name a few. 1 Abbreviations: IDU: injection drug user; PMTCT: prevent mother-to-child-transmission; STI: sexually transmitted disease; PEP: postexposure prophylaxis; PrEP: pre-exposure prophylaxis. Reference Mayer KM, Nenkatesh KK. Antiretroviral therapy as HIV prevention: status and prospects. Am J Public Health. 2010;100:1867-1876.
  2. Slide: Why Antiretroviral Agents for HIV Prevention? The prophylactic use of antimicrobial agents have been the foundation of prevention against many infections. Data from animal studies have shown that multiple antiretroviral agents decrease HIV transmission pre- or postexposure prophylaxis (PEP). In humans, the use of antiretroviral therapy is standard of care for the prevention of mother-to-child transmission of HIV as well as for occupational postexposure prophylaxis after percutaneous exposure. 1-4 The use of antiretroviral agents for HIV prevention has gained consideration because of the improved tolerability of newer agents, the potential for lower-cost generic alternatives, and the challenges encountered with other methods (eg, vaccine). 3,4 References Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med . 1994;331:1173-1180. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med . 1997;337:1485-1490. Grant RM. Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clin Infect Dis . 2010;50(suppl 3):S96-S101. Venkatesh KK, Lurie MN, Mayer KH. How HIV treatment could result in effective prevention. Future Virol. 2010;5:405-415.
  3. Estimates of per-act risk of acquisition of HIV are approximate and vary widely depending on the viral load of the source contact, the presence of sexually transmitted diseases, and other factors.
  4. Slide: Antiretroviral Systemic PrEP: Ratio of Genital:Blood Plasma Levels Concentrations of the drugs in blood plasma do not always correlate with those in the genital tract and rectum, and accumulation ratios vary between and within therapeutic classes. The mechanisms that underlie these differences have yet to be fully elucidated. 1 This slide shows the differences in genital-to-plasma ratios for antiretroviral levels in men and women. 1 Reference Nicol MR, Kashuba AD. Pharmacologic opportunities for HIV prevention. Clin Pharmacol Ther. 2010;88:598-609.
  5. Slide: What If PrEP Works? There are a number of issues that need to be addressed if PrEP is shown to be efficacious and safe. These issues include: Block other steps in the HIV life cycle? Develop drugs just for prevention. New co-formulations (generic PrEP?). Topical versus oral (VOICE and beyond). Optimal drug delivery system. How best to dose. Interaction with other prevention modalities. Optimal utilization and effectiveness may require multiple modalities.
  6. Slide: What If PrEP Works? There are a number of issues that need to be addressed if PrEP is shown to be efficacious and safe. These issues include: Block other steps in the HIV life cycle? Develop drugs just for prevention. New co-formulations (generic PrEP?). Topical versus oral (VOICE and beyond). Optimal drug delivery system. How best to dose. Interaction with other prevention modalities. Optimal utilization and effectiveness may require multiple modalities.
  7. Slide: What If PrEP Works? There are a number of issues that need to be addressed if PrEP is shown to be efficacious and safe. These issues include: Block other steps in the HIV life cycle? Develop drugs just for prevention. New co-formulations (generic PrEP?). Topical versus oral (VOICE and beyond). Optimal drug delivery system. How best to dose. Interaction with other prevention modalities. Optimal utilization and effectiveness may require multiple modalities.
  8. Both the study article and the supplemental material are available free of charge that the NEJM website until approximately December 30, when the manuscript will be published in the print edition of the Journal. The supplemental material contains important graphs and tables and additional discussion about the findings.
  9. All iPrEx participants were followed very closely throughout the study to protect their safety and to monitor for any possible adverse effects from the PrEP regimen. The FTC/TDF combination was chosen for this study because both drugs stay active in the body for long periods, allowing for once daily dosing; both drugs are approved for the treatment of HIV and have been shown to be safe; and both drugs have demonstrated protection against HIV in animal studies of PrEP, with the two drugs having shown higher levels of protection together. Both drugs are also available in patented and generic formulations.
  10. All iPrEx study participants received the same comprehensive package or prevention services designed to reduce their risk of HIV infection throughout the trial, including HIV testing, intensive safer sex counseling, condoms and treatment and care for sexually transmitted infections. Half of study participants also received the PrEP pill, while the other half received a placebo.
  11. The majority of iPrEx study participants came from the Americas. The iPrEx study began in Peru and Ecuador, and expanded to include participants in Brazil, the United States, South Africa and Thailand.
  12. Efficacy was evident in all of the analyses. The intention to treat analysis included all enrolled participants. The modified intention to treat analysis included all enrolled participants except for the 10 who were subsequently found to be viral RNA positive at the enrollment visit. The as treated analysis (50%) considered visits when pill use was recorded on 50% or more of days, based on pill counts, self-report, and pill dispensation records. The as treated analysis (90%) considered visits when pill use was recorded on 90% of days, as above. The efficacy was higher among those reporting unprotected receptive anal intercourse at enrollment (URAI). URAI was the strongest risk factor for HIV acquisition in this study, and other studies of MSM.
  13. A nested case control study was performed that included drug level analysis of blood specimens of 34 of the 36 seroconverters on the FTC/TDF arm of the study, and a set of seronegative controls also from the active arm. One timepoint per person was analyzed. In the HIV infected cases, the timepoint was the first laboratory evidence of HIV infection, whether that evidence was antibody or RNA. The seronegative controls were selected from the same sites at comparable timepoints. Emtricitabine and Tenofovir was measured in blood plasma, and emtricitabine-tri-phosphate and tenofovir-di-phosphate were measured in peripheral blood mononuclear cells. All measurements were by tandem mass spectroscopy. No drug was detected in a sample of placebo arm participants. Drug detection was more than 95% concordant between the different measurements. Overall, one or more drugs were detected in the active arm of the study in 51% of the seronegatives and 9% of the HIV cases. This contrasts with reported adherence which was more than 90% on average. Over-reporting of adherence is common in treatment and prevention trials.
  14. There were differences in mild side effects between the arms. TDF is known to decrease renal function a small amount in HIV infected persons. We also observed a trend toward more creatinine elevations in the active arm of the study. Most the creatinine elevations resolved without stopping study drug and many remained within the normal range (they were elevations only in that they increased more than 50% from the participant’s baseline). Only 5 (0.4%) of the active arm had creatinine elevations that persisted until the following visit; all resolved after stopping FTC/TDF. Four of these were rechallenged without recurrence in the creatinine elevation. Headache, nausea, and unintentional weight loss of 5% was reported more frequently in the active arm, typically in the first few weeks of pill use. The proportion affected was less than 1 in 20 participants. There were no differences between groups in diarrhea or depression and a large number of other adverse events and lab markers.
  15. Nausea was also assessed by medical history at all visits. Nausea was reported in 1 in 10 (9%) of the active arm participants and 5% of placebo users, and decreased to comparable levels at subsequent visits. This is consistent with start up symptoms that occur in some persons starting antiviral therapy. People’s long term adherence to therapy, and possibly PREP, could be enhanced if they receive supportive counseling for side effects in the first 4 weeks of pill use.
  16. Slide: Topical TDF or FTC/TDF Gel: Complete Protection From SHIV Exposure Parikh and colleagues evaluated tenofovir with or without emtricitabine as preexposure prophylaxis by using a twice-weekly repeat challenge macaque model and showed that a preexposure vaginal application of gel with 1% tenofovir DF alone or in combination with 5% emtricitabine could fully protected macaques from a total of 20 exposures to SHIV. 1 Reference Parikh UM, Dobard C, Sharma S, et al. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol . 2009;83:10358-10365.
  17. Slide: CAPRISA 004 Results: HIV Incidence HIV incidence in the tenofovir gel arm was 5.6 per 100 women-years (person time of study observation) (38 out of 680.6 women-years) compared with 9.1 per 100 women-years (60 out of 660.7 women-years) in the placebo gel arm ( P =0.017). 1 In high adherers (gel adherence &gt;80%), HIV incidence was 54% lower ( P =0.025) in the tenofovir gel arm. In intermediate adherers (gel adherence 50% to 80%) and low adherers (gel adherence &lt; 50%), the HIV incidence reduction was 38% and 28%, respectively. Tenofovir gel reduced HIV acquisition by an estimated 39% overall, and by 54% in women with high gel adherence. 1 Reference Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science . 2010;329:1168-1174.
  18. Slide: Intermittent PrEP in Macaques With Oral FTC/TDF Garcia-Lerma and colleagues demonstrated maximum protection from 14 weekly SHIV exposures when an oral pre-exposure dose 22 hours before exposure is followed by a postexposure dose at 2 hours after the exposure (hazard ratio 16.7). This protection decreases when the pre-exposure dose is administered as early as 3 and 7 days before infection (hazard ratio 15.4 and 9.3, respectively) or if the postexposure dose is delayed by 22 hours after the infection (hazard ratio 4.1). 1 Reference García-Lerma JG, Paxton L, Kilmarx PH, et al. Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci . 2010;31:74-81.
  19. Slide: New Antiretroviral Topical Microbicides This slide provides an overview of microbicides in development and their clinical development status.
  20. Slide: What If PrEP Works? There are a number of issues that need to be addressed if PrEP is shown to be efficacious and safe. These issues include: Block other steps in the HIV life cycle? Develop drugs just for prevention. New co-formulations (generic PrEP?). Topical versus oral (VOICE and beyond). Optimal drug delivery system. How best to dose. Interaction with other prevention modalities. Optimal utilization and effectiveness may require multiple modalities.
  21. Slide: HPTN 065: Testing, Linkage to Care, Treatment, Plus Lots More… HPTN 065 is a study to assess the feasibility of a community-level test, link to care, plus treat strategy (TLC-Plus) in the United States. The primary outcomes of the TLC-Plus package of interventions will be determined through measurement of change over the duration of the study in key parameters in two intervention communities. Observations in the four non-intervention control communities will help assess the influence of current trends in HIV testing and care expansion in the United States. 1 TLC-Plus is uses innovative approaches, including: 1 A community focus. Multi-component strategies that include behavioral and biomedical interventions. The use of routinely reported HIV surveillance data to determine key outcomes. A partnership with local Departments of Health and the Centers for Disease Control and Prevention. This study will serve as a proof-of-concept formative study. It will provide key information that could guide the design and anticipate the costs of a future large randomized, community-level clinical trial of full implementation of a test-and-treat strategy in the United States. Findings from this study could also inform test-and-treat efforts in other developed countries with epidemics similar to that in the United States. 1 Reference Available at: www.hptn.org.
  22. Slide: What If PrEP Works? There are a number of issues that need to be addressed if PrEP is shown to be efficacious and safe. These issues include: Block other steps in the HIV life cycle? Develop drugs just for prevention. New co-formulations (generic PrEP?). Topical versus oral (VOICE and beyond). Optimal drug delivery system. How best to dose. Interaction with other prevention modalities. Optimal utilization and effectiveness may require multiple modalities.